Companies to jointly establish new cloud-based platform for centralized management of clinical imaging and workflow applications and AI tools.
Edinburgh, UK – December 1, 2020 – Blackford, the provider of the dedicated platform for medical imaging applications and AI, today announced a partnership with Bayer to develop a new cloud-based medical imaging platform for the life science company.
Under the global development and license agreement, the two companies will create a medical imaging platform that provides cloud access to digital and AI applications throughout users’ existing workflow. Via a curated marketplace, the Bayer platform will allow healthcare professionals to access and centrally manage a range of imaging applications and AI tools from Bayer, as well as from strategic external partners.
This agreement is a continuation of Blackford’s long-standing OEM partnership approach which provides medical imaging vendors with AI marketplace and platform functionality through the resale or white-labelling of Blackford’s established technology. Blackford’s platform is already deployed in numerous hospitals, radiology groups and imaging centres across the United States, Oceania and Europe.
“Our partnership with Blackford Analysis will accelerate innovation in the field of overall disease management”, said Alexandre Salvador, new Head of Digital Business Solutions, Radiology, Bayer AG. “By driving forward AI-enabled medical imaging, we support radiologists and their teams in providing clear direction from diagnosis to care.”
Using Blackford, healthcare organizations can save time on the deployment, orchestration, management and support of multiple imaging applications and AI tools that drive clinical efficiencies and improve results by enabling radiologists to read faster. All applications are optimized to augment and deliver results within existing workflows, viewers and worklists.
“We are pleased that a leading life science company like Bayer has chosen to partner with Blackford to support the delivery of their medical imaging platform,” said Ben Panter, CEO, Blackford Analysis. “The Bayer platform will leverage Blackford’s knowledge and experience as one of the first and most widely deployed platform providers in the industry. This experience and our advanced platform technology will give Bayer the ability to help healthcare providers identify and integrate medical imaging applications and AI that benefit their practice.”
Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Its products and services are designed to benefit people by supporting efforts to overcome the major challenges presented by a growing and aging global population. At the same time, the Group aims to increase its earning power and create value through innovation and growth. Bayer is committed to the principles of sustainable development, and the Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2019, the Group employed around 104,000 people and had sales of 43.5 billion euros. Capital expenditures amounted to 2.9 billion euros, R&D expenses to 5.3 billion euros. For more information, go to www.bayer.com.
Blackford delivers a dedicated platform and service for the effective selection, deployment, orchestration and use of best-in-class medical imaging applications and AI. As the most mature and widely deployed dedicated platform provider in the industry, the company is exclusively focused on helping healthcare providers identify and integrate medical imaging applications and AI that benefit their practice. Founded in 2010, and with operations in the United Kingdom and the United States, Blackford Analysis is backed by TRI Cap, Old College Capital, and Archangel Investors. For mor information visit www.blackfordanalysis.com
Phone: +44 (0)131 473 1156